TLSI Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
12.9M
+12.9%
11.4M
+28.2%
8.9M
-32.6%
13.2M
+14.2%
11.6M
Cost of Revenue
1.8M
+18.2%
1.5M
+22.6%
1.2M
-30.2%
1.8M
-7.6%
1.9M
Gross Profit
11.1M
+12.1%
9.9M
+29.1%
7.7M
-33.0%
11.4M
+18.5%
9.7M
Operating Expenses
18.1M
-12.8%
20.7M
+28.8%
16.1M
+9.3%
14.7M
-8.9%
16.1M
R&D
3.2M
+1.7%
3.1M
-2.5%
3.2M
+25.1%
2.6M
-54.9%
5.7M
SG&A
15.6M
-5.8%
16.6M
+28.8%
12.9M
+5.9%
12.1M
-6.4%
13.0M
Operating Income
-6969000
+35.5%
-10809000
-28.5%
-8411000
-157.1%
-3271000
+49.6%
-6490000
EBITDA
-6840000
+35.9%
-10673000
-29.0%
-8276000
-163.1%
-3145000
+50.3%
-6327000
Net Income
-8854000
+3.6%
-9187000
-696.9%
1.5M
+115.8%
-9753000
+9.8%
-10811000
EPS (Basic)
$-0.15
+6.3%
$-0.16
-633.3%
$0.03
+114.3%
$-0.21
+78.1%
$-0.96
EPS (Diluted)
$-0.15
+6.3%
$-0.16
-633.3%
$0.03
+114.3%
$-0.21
+78.1%
$-0.96
Shares (Diluted)
58.5M
+0.3%
58.3M
+11.4%
52.3M
+11.1%
47.1M
+9.4%
43.1M
TriSalus Life Sciences (TLSI) — Financials